The biopharmaceutical industry continues to focus on the development of biotherapeutic monoclonal antibody (mAbs) drugs. In this article, the compatibility of SEC coupled with HRAM–MS for the analysis of mAbs is demonstrated.
Zhiqi Hao
Advertisement
Articles by Zhiqi Hao
Advertisement
Latest Updated Articles
Analysis of Monoclonal Antibodies and Their Fragments by SEC Coupled with HRAM-MSPublished: December 15th 2014 | Updated:
Advertisement
Advertisement
Trending on LCGC International
1
Navigating Adverse Reactions in GLP-1 Treatment
2
Decoding Sweet Potato Drought Resilience: Metabolomic Evidence from UPLC-MS Profiling
3
Toward Safer Diabetes Devices: GC–MS Detection of Allergens in Sensors, Pumps, and Infusion Sets
4
Advancing RNA-Based Therapeutics: IQ Consortium Experts on Optimizing Chromatographic Bioanalysis
5
